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We illustrate the potential for specialist laboratory 
networks to be used as preparedness and response 
tool through rapid collection and sharing of data. 
Here, the Emerging Viral Diseases-Expert Laboratory 
Network (EVD-LabNet) and a laboratory assessment 
of chikungunya virus (CHIKV) in returning European 
travellers related to an ongoing outbreak in Thailand 
was used for this purpose. EVD-LabNet rapidly col-
lected data on laboratory requests, diagnosed CHIKV 
imported cases and sequences generated, and shared 
among its members and with the European Centre for 
Disease Prevention and Control. Data across the net-
work showed an increase in CHIKV imported cases 
during 1 October 2018–30 April 2019 vs the same 
period in 2018 (172 vs 50), particularly an increase in 
cases known to be related to travel to Thailand (72 vs 
1). Moreover, EVD-LabNet showed that strains were 
imported from Thailand that cluster with strains of 
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the ECSA-IOL E1 A226 variant emerging in Pakistan in 
2016 and involved in the 2017 outbreaks in Italy. CHIKV 
diagnostic requests increased by 23.6% between the 
two periods. The impact of using EVD-LabNet or simi-
lar networks as preparedness and response tool could 
be improved by standardisation of the collection, qual-
ity and mining of data in routine laboratory manage-
ment systems.
Background
The rapid increase in chikungunya virus (CHIKV) cases 
in Thailand since October 2018 raised concerns in 
Europe about the potential increased risk for public 
health of CHIKV importation through returning travel-
lers [1,2]. Thailand is a popular tourist destination with 
6.5 million European travellers in 2017 alone [3]. In the 
last 3 months of 2018, Thailand reported 3,314 prob-
able and confirmed cases and in 2019, as at 27 May 
2019, 3,592 CHIKV cases were reported in 23 provinces 
[4]. Cases of CHIKV infection imported from Thailand 
into Europe and the Middle East were reported in early 
2019 [5,6].
Chikungunya is characterised by a rapid onset of 
high fever, rash and joint pain. CHIKV is an alphavi-
rus that is transmitted to humans by the bite of 
some Aedes mosquitoes; Ae. albopictus, an important 
mosquito vector for CHIKV, is established in 15 European 
countries, mainly in the south of the continent [7]. Its 
presence has resulted in autochthonous transmission 
foci initiated by returning viraemic travellers in Italy 
and France on several occasions in the past [8-13]. It 
has been suggested that the A226V mutation in the E1 
gene of the CHIKV genome could potentially influence 
the fitness of CHIKV East-Central-South African (ECSA)-
Indian Ocean lineage (IOL) strains for certain  Ae. 
albopictus  populations [14]. This variant caused the 
first European outbreak in Italy in 2007 [11] and sev-
eral autochthonous infection foci in France in 2014 and 
2017 [8,9,12]. However, in 2016 a sub-cluster of ECSA-
IOL strains without the A226V mutation emerged in 
Pakistan and neighbouring countries [15,16]. This E1 
A226 variant caused two outbreaks with hundreds of 
cases in 2017 in Italy [10,13] and experimental studies 
showed that the Pakistani variant was as efficiently 
transmitted by Italian Ae. albopictus mosquitoes as the 
E1 A226V 2007 outbreak strain [17,18].
In southern Europe the  Ae. albopictus  activity 
season typically lasts between June and October. Its 
start heightens awareness regarding the risk of local 
CHIKV transmission following the introduction of the 
virus by travel-associated viraemic cases. Hence, ques-
tions arose in March 2019 with European public health 
authorities about the threat of the CHIKV outbreak in 
Thailand to Europe. An assessment of such threat would 
be informed by the number of diagnostic requests and 
imported cases as well as the CHIKV strain currently 
circulating in Thailand. Here, we illustrate the potential 
of specialist laboratory networks as preparedness and 
response tool by rapid collecting and sharing of data 
and laboratory-diagnosed CHIKV patients related to 
the outbreak in Thailand.
Emerging Viral Diseases-Expert Laboratory 
Network
International networking is essential for preparedness 
and response to emerging infectious disease events. 
Accurate laboratory diagnosis of emerging pathogens 
like CHIKV may be challenging, which can be problem-
atic as it forms the basis for adequate surveillance, 
clinical and public health responses and monitoring of 
the effectiveness of prevention and intervention efforts 
[19]. These notions were recognised and in response, 
the European Centre for Disease Prevention and Control 
(ECDC) funded EVD-LabNet (https://www.evd-labnet.
eu/). EVD-LabNet represents a laboratory and knowl-
edge platform for support of clinical and public health 
preparedness and response through laboratory capac-
ity and capability building. Moreover it provides access 
for ECDC, national public health authorities and its 
member laboratories to reference diagnostics, exper-
tise and knowledge exchange [20,21]. EVD-LabNet 
comprises 61 expert laboratories in 30 European 
Union and European Economic Area (EU/EEA) coun-
tries, seven laboratories in seven EU pre-accession 
countries, three in two other European countries and 
six in six non-European countries. Among the EVD-
LabNet laboratories, 51 have the capacity to diagnose 
CHIKV infection by molecular tests and 44 by serologi-
cal tests. Moreover, 22 and 29 laboratories have indi-
cated to have the capability to isolate the virus and to 
characterise it through full genome sequencing and/or 
sequencing of PCR amplicons respectively. Sequence 
information is of importance for risk assessment and 
for the optimisation and evaluation of available diag-
nostic tests.
Chikungunya cases imported from 
Thailand into Europe and Israel
To substantiate the need for a heightened awareness 
for a possible increased public health risk of import 
of CHIKV cases from Thailand into Europe, we investi-
gated whether the outbreak was reflected in the diag-
nostic requests and outcomes at EVD-LabNet member 
laboratories. Furthermore, we investigated whether 
genetic information, in particular about the E1 gene, on 
circulating strains was available. On 27 March 2019, the 
51 EVD-LabNet laboratories that offer molecular CHIKV 
diagnostics were initially asked by email whether they 
had diagnosed any CHIKV cases related to the then 
ongoing outbreak in Thailand and if sequence informa-
tion was (or could) become available.
In a follow up email on 2 May 2019, responding labo-
ratories were asked for more details about the CHIKV 
diagnostic data collected between 1 October 2018 
and 30 April 2019 relative to the same period from 
2017 to 2018. In particular, laboratories were asked to 
share available information about CHIKV E1 sequences 
obtained from viraemic patients. These data are 
shown in  Table 1. They were used to further inform 
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Table 1
Chikungunya virus diagnostic requests and results, EVD-LabNet laboratories, 1 October 2017–30 April 2018 and 1 October 
2018–30 April 2019
 Reference Laboratories, country 
(town)
1 October 2017–30 April 2018 1 October 2018–30 April 2019
Number of patients Number of patients Sequences from 
CHIKV infected 
patients related to 
Thailand outbreak 
 
(no., sequence)
If yes: 
 
presence 
of the E1 
A226V 
mutation
Positive for 
CHIKV /total 
testeda
Positive for CHIKV/
total testeda known 
to be from Thailand
Positives/ 
total 
testeda for 
CHIKVa
Positives/total 
testeda known to 
be from Thailand
Austria (Vienna) 1/199 0/19 9/266
8/26 
 
(5 from Krabi, 2 
from Ko Samui, 1 
unknown)
Y (5 patients, E1 
partial sequence) N
Belgium ( Antwerp) 1/724 0/22 12/751 4/30 N NA
Bulgaria (Sofia) 0/0 NA 0/0 NA NA NA
Croatia (Zagreb) 0/1 0/0 0/1 0/0 NA NA
Finland (Helsinki) 1/101 0/15 10/64 10/24 Y (2 patients, full genome) N
France (Marseille) 0/240 0/unknown 10/1236 1/42 N NA
France (Paris) 0/0 NA 0/0 0 N NA
Germany (Berlin) 2/43 Unknown 0/17 0/unknown NA NA
Germany (Hamburg) 18/1,283 Unknown 51/1263 1/unknown N NA
Germany (Leipzig) 0/0 NA 0/0 NA NA NA
Greece (Thessaloniki) 0/2 0/0 0/0 NA NA NA
Greece (Athens) 0/3 0/0 0/2 0/0 NA NA
Hungary (Budapest) 2/146 0/32 2/120 0/29 NA NA
Ireland (Dublin) 0/45 Unknown 2/48 1/unknown N NA
Italy (Bologna) 2/107 0/4 4/75 4/7 Y (1 patient, E1 partial sequence) N
Italy (Rome, INMI) 0/170b 0/15 2/135 1/12 Y (1 patient, E1 partial sequence) N
Italy (Rome, ISS) 1/42b 0/2 3/39 1/5 N NA
Italy-(Padua) 2/165 0/8 3/137 1/16 N NA
Italy (Turin) 0/43 0/3 1/46 1/7 N NA
Luxembourg (Luxembourg) 0/81 0/4 0/92 0/9 NA NA
Serbia (Belgrade) 1/1 0/0 0/0 0/0 NA NA
Slovenia (Ljubljana) 1/20 Unknown 1/26 1/1 Y (1 patient, full genome) N
Spain (Barcelona)
0/273 
 
2c
0/unknown
0/287 
 
1c
0/unknown 
 
1c
Y (1 patientc, E1 
partial sequence) N
Spain (Granada) 2/43 1/13 0/31 0/5 NA NA
Spain (Madrid) 8/375 0/6 2/492 0/8 NA NA
Sweden (Solna) 3/94 0/unknown 48/514 32/unknown N NA
The Netherlands (Bilthoven) 1/237 0/6 2/218 1/8 N NA
The Netherlands (Rotterdam) 1/175 0/3 5/218 4/13 N NA
Israel (Tel Aviv) 3/85 Unknown 6/75 1/unknown Y (1 patient, E1 partial sequence) N
Total 50/4,698 1/152 173/6,153 72/242  
CHIKV: chikungunya virus; EVD-LabNet: Emerging Viral Diseases-Expert Laboratory Network; N: no; NA: not applicable; Y: yes.
a Includes molecular and/or serology requests.
b Only travellers from endemic regions different from Italy in 2017.
c Cases diagnosed in September (outside the period of study).
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the assessment of risk of local transmission by  Ae. 
albopictus.
Within 2 days, 39 laboratories (representing 21 EU/EEA 
countries, two EU pre-accession countries, two other 
European countries and one non-European country) 
responded to the initial request indicating whether 
or not they had diagnosed CHIKV cases and obtained 
associated sequences related to the increased num-
bers of CHIKV cases reported in Thailand. Of 39 
respondents, 17 (in 12 EU/EEA, one other European 
and one non-European country) indicated to have diag-
nosed CHIKV cases related to the outbreak in Thailand. 
Of 39 respondents, 29 laboratories in 18 countries 
(17 EU/EEA and one non-European) answered to the 
more detailed second request for information; three 
laboratories (in three EU/EEA countries) had no CHIKV 
requests in either of the specified time periods.
Between 1 October 2018 and 30 April 2019, 6,153 
patients were tested by 26 laboratories for CHIKV of 
which 173 (2.8%) were indicated to be probable and con-
firmed cases of CHIKV infection based on national case 
definitions. Among 242 patients with known travel his-
tory to Thailand, 72 (29.8%) were diagnosed as prob-
able and confirmed CHIKV cases. A 23.6% increase in 
the total number of patients tested for CHIKV (regard-
less of travel destination) was observed for the period 
from 1 October to 30 April in 2018 vs 2019.
During the same period in 2018, 4,698 patients were 
tested for CHIKV infection of which, 50 (1.1%) were 
identified as probable and confirmed CHIKV cases; 
only one probable case was known to be acquired 
in Thailand. One laboratory in Spain diagnosed two 
CHIKV cases in September 2017 and one in September 
2018. As the latter case was a traveller returning from 
Thailand, sequence information related to this case 
was included in this study.
Phylogenetic analysis
During the study period, CHIKV sequences were avail-
able for 12 patients, linked to travel to Thailand, in 
seven laboratories in six countries: nine partial E1 
sequences and three full genome sequences. None 
of the sequences carried the E1-A226V mutation. The 
partial sequences analysed of the Thailand strains are 
listed in Table 2.
Phylogenetic analysis was performed based on E1 par-
tial region 10194–11170 (reference strain CHIKV S27, 
GenBank AF369024) that was the minimal overlap in all 
sequences provided. As shown in the  Figure, the par-
tial E1 sequences of the strains imported from Thailand 
clustered together with the CHIKV ECSA-IOL strain that 
emerged around 2004 resulting in widespread out-
breaks. Particularly, they clustered in the sub-group 
comprising sequences of the recently emerged ECSA-
IOL variant (‘Pakistan ECSA-IOL’ variant group, Figure) 
involved in the 2017 epidemic in Pakistan [15] and Italy 
[10,17,22]. All European ex-Thailand sequences were 
highly similar, with nt differences ranging between 0 
and 0.006% in the 976 bp overlapping fragment that 
was analysed.
Discussion
In response to the Thailand-CHIKV alert, EVD-LabNet 
was able to rapidly inventory and share among its 
members and with ECDC, data on laboratory-diagnosed 
imported CHIKV cases and sequences. This information 
directly enhanced risk assessment at ECDC by inform-
ing experts during the daily round table meeting where 
Table 2
Overview of chikungunya virus sequence data provided by EVD-LabNet, 2019
Reference Laboratories GeneBank accession number
5’-3’ ends of sequenced 
amplicona
Sample Collection 
Date
Site of Origin of the 
imported case (if known)
Austria, Vienna.AUT/02.2019 MN053046 10211–10917 7 February 2019 Unknown
Austria, Vienna.AUT/09.2019 MN053047 10194–10932 25 February 2019 Thailand-Krabi
Austria, Vienna.AUT/09.2019/2 MN053048 10194–10985 25 February 2019 Thailand-Krabi
Austria, Vienna.AUT/12.2019 MN053049 10194–10899 21 March 2019 Thailand-Krabi
Austria, Vienna.AUT/12.2019/2 MN053050 10194–10881 21 March 2019 Thailand-Krabi
Finland, Helsinki-1 MN075149 Full genome 25 February 2019 Thailand-Phuket
Finland, Helsinki-2 MN075150 Full genome 27 February 2019 Thailand-Phuket
Italy (Bologna) MN047314 9994–11312 2 March 2019 Unknown
Italy (Rome, INMI) MK986662 10180–10922 4 February 2019 Unknown
Israel (Tel Aviv) MK992771 10525–11170 17 February 2019 Unknown
Slovenia (Ljubljana) MK848202 Full genome 21 November 2018 Unknown
Spain (Barcelona) MN080498 10254–10712 6 September 2018 Unknown
EVD-LabNet: Emerging Viral Diseases-Expert Laboratory Network.
a Reference sequence for determination of 5’-3’ ends of sequenced amplicons: CHIKV S27 – ECSA Africa prototype, GeneBank accession 
number: AF369024.
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Figure 
Neighbour-joining phylogenetic analysis of partial E1 region sequences derived from chikungunya virus-positive cases 
imported from Thailand into Europe, October 2018–April 2019
 MN075149 Finland 2019 ex Thailand
 MN075150 Finland 2019 ex Thailand
 KY751908 India 2016
 MF774616 Pakistan 2016
 MG049915 Italy 2017
 MH507158
 MF774617 Pakistan 2016
 MF740881 Pakistan 2016
 MF740874 Pakistan 2016
 MF573011 India 2015
 MH754507 Italy 2017
 MF774618 Pakistan 2016
 MF774614 Pakistan 2016
 MF740877 Pakistan 2016
 MF740876 Pakistan 2016
 MF774619 Pakistan 2016
 MF774615 Pakistan 2016
 KY057363 India 2016
 MF740880 Pakistan 2016
 MG697280 Bangla Desh 2017
 MG912993 Bangla Desh 2017
 MG697265 Bangladesh 2017
 MK848202 Slovenia 2019 ex Thailand
 MF740879 Pakistan 2016
 MF740878 Pakistan 2016
 MK992771 Israel 2019 ex Thailand
 MN053047 Austria 2019 ex Thailand
 MN053048 Austria 2019 ex Thailand
 MH400249 Italy 2017
 MF773566 Bangla Desh 2017
 MG697266 Bangla Desh 2017
 MK120196 Italy 2017
 MK120199 Italy 2017
 MK120195 Italy 2017
 MK120200 Italy 2017
 MK120197 Italy 2017
 MK120194 Italy 2017
Calabria
 MF774613 Pakistan 2016
 MN053046 Austria 2019 ex Thailand
 MF503628
 MN053049 Austria 2019 ex Thailand
 MN053050 Austria 2019 ex Thailand
 MN047314 Italy 2019 ex Thailand
 MG697276 Bangla Desh 2017
 MN080498 Spain 2018 ex Thailand
 MG697279 Bangla Desh
 MK986662 Italy 2019 ex Thailand
Pakistan-IOL
 MF573010 India 2010
 MF573005 India 2015
 MF573006 India 2017
 MF573009 India 2015
 HM159387 India 2010
 FR846304 India 2010
 MF573002 India 2015
 MF573001 India 2015
 FJ445487 Singapore 2010
 JF272480 India 2006
 EF451147 India 2006
 FJ513638 Sri Lanka 2008
 FJ513674 Sri Lanka
 FJ513672 Sri Lanka 2008
 EU287996 India 2008 A226V
 EU170523 India 2006
 EU287997 India 2006 A226V
 HQ846359 China 2010
 EU287998 India 2008 A226V
0.0010
ECSA-IOL sequences available from the European Nt Archive (ENA) data bank were included in the analysis. Phylogenetic analysis was performed on E1 partial 
region 10194–11170 (reference strain CHIKV S27, GenBank AF369024) that was the minimal overlap in all sequences provided. Gaps in the alignment due to 
differences in the length of sequenced amplicons were ignored in the distance model. The phylogenetic tree was constructed using Tamura-Nei model with 1,000 
bootstrap reiterations. Two major clusters are highlighted in the Figure: one cluster comprising the ex-Thailand sequences reported here and a second cluster, 
which includes sequences with the A226V mutation in the envelope E1 gene (indicated with a black circle). The scale bar indicates the percentage of diversity. 
The branch length of 0.001 was chosen to better show the relatedness of ex-Thai sequences. For each sequence in the tree, GenBank accession number/country 
of origin of the infection/year of the infection are reported. Sequences characterised in this study are indicated by a black triangle.
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active communicable disease threats are reviewed. 
While CHIKV is classified as a notifiable disease in 
the EU [23], reporting of pathogens like CHIKV to ECDC 
through the European surveillance system (TESSy) 
does not happen on a real-time basis with regard to 
returning travellers. TESSy data are usually reported in 
annual epidemiological reports with surveillance atlas 
data typically published ca 1 year late [24]. Furthermore, 
regular surveillance systems do mostly not collect data 
on the total numbers of diagnostic requests that labo-
ratories have received. Such information is, however, 
relevant for an adequate assessment of the general 
level of preparedness and awareness among physi-
cians and current pressure on laboratory response 
through increased diagnostic requests.
The exchange of snapshot laboratory data within a 
network such as EVD-LabNet has the advantage of a 
timely provision of essential data and opens the pos-
sibility to direct further investigations, for example 
through phylogenetic characterisation targeting the 
presence of virulence and/or vector competence mark-
ers and validating common diagnostic tests. However, 
most laboratories processing vast amounts of diag-
nostic requests indicated that their routine labora-
tory information management systems are not set up 
to enable easy extraction of answers to such queries, 
and some epidemiological parameters, like travel des-
tination, are often not provided. Furthermore, a lack of 
standardisation across Europe of e.g. protocols (includ-
ing specific tests used and interpretation), clinical and 
laboratory case definitions and local situation-driven 
differences in test requesting behaviour of clinicians 
will bias data collection. Hence, the potential impact of 
international laboratory networks as preparedness and 
response tool can be further enhanced by improvement 
and standardisation of collection, quality and mining 
of data.
Nevertheless, we observed a 23.6% increase in CHIKV 
diagnostic requests across the participating laborato-
ries during the study period. Moreover, we observed 
an increase in the number of positive laboratory cases, 
and in particular an increase of CHIKV-infected travel-
lers from Thailand. The place of infection was unknown 
for many diagnostic requests and confirmed cases, 
making it likely that the number of requests and cases 
associated with travel to Thailand might be under 
reported in this study and highlighting the importance 
of a complete travel anamnesis not only for diagnostic 
and clinical purposes but for epidemiological analysis 
as well [25]. The E1-A266V mutation was not present in 
the partial CHIKV sequences generated from 12 of 73 
imported cases from Thailand (including the Spanish 
case from September 2018), but the phylogenetic anal-
ysis revealed a high similarity with the strain involved 
in a large outbreak in the Indian sub-continent and 
the  Ae. albopictus-sustained outbreak that occurred 
in Italy in 2017. Based on information from previous 
CHIKV outbreaks in Thailand, an E1 A226V strain was 
expected to cause the 2018–2019 outbreak in Thailand 
[26,27]. The circulation of E1 A226 CHIKV in Thailand 
highlights the interconnectivity in Asia and the occur-
rence of outbreak strain replacement in endemic areas.
Conclusion
The rapid data collection within EVD-LabNet showed 
that an increased awareness existed among physicians 
of the possibility of travellers returning from Thailand 
with an acute CHIKV infection. The timely sharing of 
the data within the network and with ECDC alerted the 
network that a further increase in diagnostic requests 
could be expected while it stressed the need for aware-
ness that with the start of the vector activity season 
in Europe and the simultaneous upcoming peak in 
vector activity in the rainy season in Thailand (June–
October) increasing numbers of returning viraemic trav-
ellers could have been the source for autochthonous 
CHIKV transmission in areas with competent vector 
species while the outbreak in Thailand was ongoing. 
International laboratory strengthening networks like 
EVD-LabNet have the opportunity to rapidly collect a 
European overview of imported laboratory cases and 
associated critical sequence information, and thus 
have the potential to inform risk assessments of the 
public health sector with directly relevant information 
thereby filling an important role in strengthening pre-
paredness and response.
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